MaaT Pharma announces the initiation of coverage of its stock by Stifel with a buy recommendation and a price target of 16 euros.
With a study published today, Stifel, an American investment bank, initiated coverage today of MaaT Pharma with a buy recommendation and a price target of 16 euros.
This new coverage reinforces the visibility of MaaT Pharma among international institutional investors, particularly American ones. This is in addition to the coverage already carried out by the brokerage firms Gilbert Dupont/Societe Generale Group, Kepler Cheuvreux, KBC Securities, Kempen and Portzamparc/BNP Paribas Group. The latter are all positioned for purchase, with a consensus for the price target at 15.20 euros.
To receive all financial information from MaaT Pharma in real time and for any questions, you can contact us via the following address: [email protected]